摘要
The prevalence of diabetic retinopathy(DR)continues to increase in pregnant females;these individuals are also at a higher risk of disease progression.The lack of evidence regarding the safety and efficacy of current treatment options in pregnancy makes disease management particularly challenging.All pregnant women with diabetes should have a prenatal DR screening,as well as receive counseling regarding the progression and management of DR during pregnancy.Optimal blood glucose and blood pressure control should be encouraged.For patients with proliferative diabetic retinopathy(PDR)in the absence of visually significant diabetic macular edema(DME),panretinal photocoagulation(PRP)remains a safe and effective treatment option.Visually significant DME can be treated with focal laser if areas of focal leakage are identified in the macula on fluorescein angiogram,intravitreal steroids or anti-vascular endothelial growth factor(VEGF)agents,The theoretical risk of anti-VEGF agents to the fetus should be considered and the patients should be extensively counselled regarding the risks and benefits of initiating anti-VEGF therapy before initiating treatment.When the decision is made to treat with anti-VEGF agents,Ranibizumab should be the agent of choice.In conclusion,ophthalmologists should make treatment decisions in pregnant patients with DR on a case-by-case basis taking into consideration disease severity,risk of permanent threat to vision,gestational age,and patient preferences.
